.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC22_Spesolimab.Spesolimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC22_Spesolimab.Spesolimab| name: | Spesolimab |
| ATC code: | L04AC22 | route: | intravenous |
| n-compartments | 2 |
Spesolimab is a humanized monoclonal antibody targeting the interleukin-36 receptor. It is used primarily for the treatment of generalized pustular psoriasis (GPP) flares in adults and received FDA approval in 2022. Spesolimab modulates inflammatory pathways and is administered as an intravenous infusion.
Pharmacokinetic parameters reported for adult patients with generalized pustular psoriasis after a single intravenous infusion of spesolimab at the recommended loading dose.
Cao, G, et al., & Zhang, J (2024). Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study. Advances in therapy 41(9) 3557–3568. DOI:10.1007/s12325-024-02940-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39039387